A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated

Study Overview
=================
Brief Summary
-----------------
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics and pharmacodynamics following multiple rising intravenous doses of BI 3032950 in healthy male subjects and postmenopausal or surgically sterilised female subjects (women not of child bearing potential (WNOCBP)).

Official Title
-----------------
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Intravenous Doses of BI 3032950 in Healthy Male and Female Subjects (Single-blind, Randomised Within Dose Groups, Placebo-controlled Parallel-group Design)

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: BI 3032950
* Drug: Placebo matching BI 3032950


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male subjects and female subjects not of child bearing potential (women not of child bearing potential (WNOCBP)) - postmenopausal or surgically sterilised female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests Age of 18 to 65 years (inclusive) Body mass index (BMI) of 18.5 to 29.9 kg/m^2 (inclusive) Signed and dated written informed consent in accordance with International conference on harmonisation-good clinical practice (ICH-GCP) and local legislation prior to admission to the trial Male subjects (including male subjects with pregnant partners) who meet any of the criteria listed in the protocol for a highly effective contraception from the first administration of trial medication until the end of study (EoS) visit. Postmenopausal or surgically sterilised female subjects (WNOCBP) who are: Confirmed surgically sterilised (including hysterectomy, bilateral salpingectomy and bilateral oophorectomy), or Postmenopausal, defined as at least 1 year of spontaneous amenorrhea without an alternative medical cause Further inclusion criteria apply. Exclusion Criteria: Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 100 beats per minute (bpm); in case of documented 'white coat hypertension' the decision for eligibility is left to the investigator Any laboratory value outside the reference range that the investigator considers to be of clinical relevance Any evidence of a concomitant disease assessed as clinically relevant by the investigator Further exclusion criteria apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BI 3032950: Dose group 1<br> | Drug: BI 3032950<br>* BI 3032950<br>|
| Experimental: BI 3032950: Dose group 2<br> | Drug: BI 3032950<br>* BI 3032950<br>|
| Experimental: BI 3032950: Dose group 3<br> | Drug: BI 3032950<br>* BI 3032950<br>|
| Experimental: BI 3032950: Dose group 4<br> | Drug: BI 3032950<br>* BI 3032950<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo matching BI 3032950<br>* Placebo matching BI 3032950<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of any treatment-emergent adverse event |  | Up to Day 137 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator |  | Up to Day 137 | 
| Area under the concentration-time curve of the analyte in serum over a uniform dosing interval τ (AUCτ,) |  | From Day 22 to Day 134 | 
| Maximum measured concentration of the analyte in serum (Cmax) |  | From Day 22 to Day 134 |